Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056 · View on ClinicalTrials.gov ↗
Study Summary
This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits.
Conditions Studied
Interventions
- DRUG Atogepant 60 mg
- DRUG Propranolol 160 mg
- DRUG Topiramate 100 mg
Study Locations (18)
Arizona
- Northern Arizona Healthcare — Flagstaff
- Mayo Clinic Arizona — Phoenix
California
- USC Keck — Los Angeles
- Clinical Research Institute — Los Angeles
Florida
- Mayo Clinic Florida — Jacksonville
- Apple Med Research — Miami
Colorado
- University of Colorado Anschutz Medical Campus — Aurora
Minnesota
- Mayo Clinic — Rochester
Missouri
- Washington University St Louis — St Louis
Nevada
- Advanced Research Institute Reno — Reno
New Jersey
- JFK Neuroscience Institute — Edison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,335 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06972056
The ClinicalTrials.gov registry entry for NCT06972056 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,335 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 3,246 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions — of which Atogepant 60 mg is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06972056 reports 18 study locations spanning 15 distinct geographic areas — top geographies include Arizona, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06972056 about?
NCT06972056 is a clinical study titled "Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study". This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerab...
What is the current status of trial NCT06972056?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,335 participants. The study started on 2025-07-09. Estimated completion is 2029-12-01.
What conditions does trial NCT06972056 study?
This clinical trial studies the following conditions: Migraine. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06972056?
The interventions under investigation include: Atogepant 60 mg (DRUG), Propranolol 160 mg (DRUG), Topiramate 100 mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06972056?
This trial is sponsored by Mayo Clinic, which has 3,246 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06972056 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.